Evolution of disease outcomes in schizophrenia: Results from the “cohort for the general study of schizophrenia (CGS)” with 3 years of follow-up
Jalbert, J.J, Rossignol, M, Rouillon, F, Astruc, B, Benichou, J, Abenhaim, L, Grimaldi-Bensouda, L
Published in Value in health (01.05.2014)
Published in Value in health (01.05.2014)
Get full text
Journal Article
Benefits of a patient-assisted medication adherence program for long-acting injectable risperidone on high-cost outcomes in schizophrenia
Astruc, B, Jalbert, J.J, Rouillon, F, Rossignol, M, Baylé, F, David, B, Bennoune, R, Avouac, B, Abenhaim, L, Grimaldi-Bensouda, L
Published in Value in health (01.05.2014)
Published in Value in health (01.05.2014)
Get full text
Journal Article
1149P Factors associated with not receiving first-line (1L) immune checkpoint inhibitor (ICI) treatment among patients (pts) with advanced NSCLC and high programmed cell death-ligand 1 (PD-L1) expression: An evaluation by age
Feliciano, J., Wu, N., Ge, W., Quek, R., Gleeson, M., Jalbert, J.J., Hsu, M.L., Harnett, J.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1105P Outcomes of real-world (RW) patients (pts) with advanced NSCLC (aNSCLC) and high programmed cell death-ligand 1 (PD-L1) expression receiving first line (1L) immune checkpoint inhibitor (ICI) therapy
Hsu, M.L., Ge, W., Wu, N., Quek, R., Liu, J., Jalbert, J.J., Rietschel, P., Feliciano, J., Harnett, J.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
673 Real-world persistence with dupilumab among adults with atopic dermatitis (AD)
Silverberg, J., Guttman-Yassky, E., Gadkari, A., Kuznik, A., Mallya, U.G., Mastey, V., Zhang, H., Chen, Z., Chen, C., Korotzer, A., Sierka, D., Fenton, M.C., Kaur, M., Jalbert, J.J.
Published in Journal of investigative dermatology (01.05.2019)
Published in Journal of investigative dermatology (01.05.2019)
Get full text
Journal Article
PMH6 - Evolution of disease outcomes in schizophrenia: Results from the “cohort for the general study of schizophrenia (CGS)” with 3 years of follow-up
Jalbert, J.J., Rossignol, M., Rouillon, F., Astruc, B., Benichou, J., Abenhaim, L., Grimaldi-Bensouda, L.
Published in Value in health (01.05.2014)
Published in Value in health (01.05.2014)
Get full text
Journal Article
PMH12 - Benefits of a patient-assisted medication adherence program for long-acting injectable risperidone on high-cost outcomes in schizophrenia
Astruc, B, Jalbert, J.J., Rouillon, F., Rossignol, M., Baylé, F., David, B., Bennoune, R., Avouac, B., Abenhaim, L., Grimaldi-Bensouda, L.
Published in Value in health (01.05.2014)
Published in Value in health (01.05.2014)
Get full text
Journal Article